Links from our newsletters
You are interested in the studies we introduced in our latest newsletters?
Here we linked them for you.
"The Power of Sample Dilution"
Limited Sample Volume
While microsampling had been a topic mostly discussed in pre-clinical studies with small animals or rare matrices, nowadays many people have experienced microsampling themselves - for example when they had to do a Covid-19 test.
Specimen collected may be
- Nasopharyngeal or oropharyngeal mucus
- Nasal wash or aspirate
Other rare matrices often require even more invasive procedures:
- Cerebrospinal fluid - Lumbar punction
- Aqueous humor - Syringe injection
- Bronchoalveolar lavage fluid - Tracheal washes
"GLP / GCP Bioanalytical Service"
Working with rare matrices or invasive methods requires microsampling - we can work with sample volumes down to 1 µl.
Discover our AnySource® Dilution Technology. We can make more out of small sample volumes, while keeping ultra sensitive detection by exponential signal amplification via Imperacer®.
"Cytokine Storm Biomarkers"
Several studies investigating severe COVID-19 cases, cite a hyperactivation of the inflammatory response, leading to a cytokine release syndrom, also called cytokine storm.
Many reports show elevated levels of IL-1, IL-6 , TNF-α and C-reactive protein (CRP), additionally, a protective effect for blood type 0 is discussed.
Read more in the following studies.
Levi, M. et al. (2020) Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 7(6): e438–e440.
Kermali, M. et al. (2020) The role of biomarkers in diagnosis of COVID-19 – A systematic review. Life Sci 117788.
Chen, L. et al. (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Chinese J Tuberculosis Respir Dis 43(0):E005
Guan, W. et al. (2020) Clinical Characteristics of Coronavirus Disease 2019 in China. NEJM. 382: 18
Wang, W. et al. (2020) The definition and risks of Cytokine Release Syndrome-Like in 11 COVID-19-Infected Pneumonia critically ill patients: Disease Characteristics and Retrospective Analysis. medRxiv
"20 Years Immunoassay Expertise"
Chimera Biotec Celebrates!
Starting in 2000, with our proprietary Immuno-PCR platform Imperacer®, Chimera has specialized in ultra sensitive GLP/GCP bioanalytical support for all phases of drug discovery.
Get your assay! Get excellence!
♦ GLP / GCP test facility
♦ Non-regulated, preclinical & clinical support
♦ Compliant with FDA & EMA guidances
♦ Ultra sensitive immunoassay platforms
♦ Assay feasibility
♦ Full assay devevlopment services
♦ Kit-based services
Ever wondered how
companies come up
with their names?
This is our story:
A Chimera is a mixed being in Greek mythology:
“She was of divine stock, not of men, in the fore part a lion, in the hinder a serpent, and in the midst a goat, breathing forth in terrible wise the might of blazing fire.” (Homer, Iliad 6,180 ff.)
Our Chimera is the Immuno-PCR platform Imperacer®, in which antibody-DNA conjugates combine ELISA-type immunoassay setup with exponential PCR read-out:
“She was of ultra sensitivity, in the fore part antibody, in the hinder DNA, enabling forth in outstanding sensitive wise the might of groundbreaking science.”
Bring together Imperacer®, AnySource® and Chimera´s 20 years of experience in beyond ELISA sensitive immunoassays, combining ultra sensitivity, broad assay range and minimal sample volume requirement.
That´s why Chimera Biotec: We provide optimal assay development for your target and bioanalysis under GLP/GCP regulations.
"Bispecific T Cell Engager - Their Role in Immuno-Oncology"
Here, Ma et al. (2020) describe T cell engagers (TCEs) binding to the tumor marker CEA (serum carcinoembryonic antigen) on cancer cells
and CD3 on T cells in the tumor compartment to form bivalent TCE ternary complex (biTTC).
They use a quantitative systems pharmacology (QPS) model to explore TCE efficiency, identify potential biomarkers
and can even predict patient-specific response to TCE treatment.
We routinely develop and validate ultra sensitive PK assays for GLP/GCP regulated bioanalytical sample testing support of bispecific antibody-based therapies, such as TCRs, for treatment of various malignancies.
Chimera´s AnySource® sample dilution minimizes matrix effects, enabling therapeutic antibodies target detection in the presence of ~ 1,000,000-fold excess of endogenous antibodies.
We offer complete service packages (PK/PD, Immunogenicity, Biomarker) across multiple platforms.
"Neurodegenerative Diseases - Bioanalytical Solutions"
Here, Yoo et al. (2020) suggest soluble Aβ*56 and AβO as potential biomarkers for AD in nasal discharge.
While increased levels in Aβ*56 alone can indicate mild AD, additionally increased AβO levels give hint to a moderate stage.
This suggests soluble Aβ*56 and AβO as potential biomarkers for AD in nasal discharge.
To address the low oral bioavailability and side effects of levodopa, Arisoy et al. (2020) used nano-sized drug carriers for nose to brain delivery.
The levodopa-coated biocompatible nanoparticles prolonged release up to 9h and improved locomotor activity in Parkinson´s Diesease model in mice.
Please feel free to contact Chimera Biotec’s team of dedicated scientists for more in-depth information. We are looking forward to provide you with the immunoassay to exceed your highest expectations.